Template:Immunohistochemistry evaluation of invasive breast cancer
Revision as of 12:09, 28 September 2020 by Mikael Häggström (talk | contribs) (→Immunohistochemistry: Formatting)
Immunohistochemistry
- Ki-67 index:[1]
- At least three high-power (×40 objective) fields should be selected
- At least 500 malignant invasive cells should be counted, unless a protocol clearly states reasons for fewer being acceptable.
- The invasive edge of the tumor should be scored
- If a comparisons must be made between core biopsies and sections from an excision, evaluation of the latter should be across the whole tumor.
- Only nuclear staining counts. Staining intensity of a positive nucleus is not relevant.
- HER2/neu score or status:
Score[2] | Status[2] |
---|---|
0 to 1+ | HER2 negative (not present) |
2+ | Borderline |
3+ | HER2 positive |
Notes
Main page
References
- ↑ Dowsett, M.; Nielsen, T. O.; A'Hern, R.; Bartlett, J.; Coombes, R. C.; Cuzick, J.; Ellis, M.; Henry, N. L.; et al. (2011). "Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group ". JNCI Journal of the National Cancer Institute 103 (22): 1656–1664. doi: . ISSN 0027-8874.
- ↑ 2.0 2.1 . IHC Tests (ImmunoHistoChemistry). Breastcancer.org. Retrieved on 2019-10-04. Last modified on October 23, 2015
Image sources